Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders Carlisle Companies Inc (CSL) and Arcturus Therapeutics (ARCT) announced that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Immunovant Inc in the NEWS Immunovant, Inc. (IMVT) announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of its product IMVT-1402 in healthy adults. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT . . . This content is for paid subscribers. Please click here to subscribe …

Anavex Life Sciences Granted US Patent Anavex Life Sciences (AVXL) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) granted them conditional marketing authorization for CASGEVYTM (exagamglogene autotemcel ), a CRISPR/Cas9 gene . . . This content is for paid subscribers. Please …

CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics (CRSP) today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease at the American Heart Association (AHA) Scientific Sessions 2023. The data will be presented on Saturday, November 11, 2023, in two oral sessions, entitled: "CTX310: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces ANGPTL3 Protein . . . This content …

ImmunoGen in the NEWS Immunogen (IMGN) - a developer of  antibody-drug conjugates (ADCs) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. From ImmunoGen Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “Building on the momentum generated in the first half of 2023, we delivered a . . . This content …

CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics (CRSP) announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of Sickle Cell Disease (SCD) in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa . . . This content is for paid subscribers. Please click here to subscribe …

Beam Therapeutics in the NEWS Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to acquire certain rights under . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Intellia Therapeutics' NTLA-2001 Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development.   Today, October 18, 2023, Intellia Therapeutics (NTLA) announced that the U.S. Food and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip Akero Therapeutics (AKRO)

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ Pediatric Study evaluating the safety, efficacy and tolerability of the firm’s product crinecerfont treating children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Disease Congenital adrenal hyperplasia refers to a group of genetic conditions that result in an enzyme deficiency that alters . . . …

Pliant Therapeutics in the NEWS Treating Primary Sclerosing Cholangitis  Pliant Therapeutics (PLRX) today announced positive data from a Phase 2a INTEGRIS-PSC clinical trial of the firm’s product bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. PSC is a rare, progressive liver disease of unknown origin, which frequently occurs in the setting of . . . This content is for …

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary results indicate that the stockholders of the firm have voted to approve the Company’s previously announced acquisition (the “Merger”) by Biogen (BIIB). Around 99.65% of the votes cast by the Company’s Class A common stockholders and Class B common stockholders, voting as . . . This content is for …

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene therapy firm, announced that the U.S. FDA has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of March 18, 2024. From Orchard Therapeutics Bobby Gaspar, M.D., …

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 CAHtalystTM Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). The Phase 3 study met its primary endpoint at Week 24, demonstrating that . . . This content is for paid subscribers. Please click here to …

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and once daily investigational compound paltusotine achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study.   PATHFNDR-1 study enrolled participants with acromegaly who were biochemically controlled on octreotide or lanreotide depot monotherapy. PATHFNDR-1 is . . . This content is for …

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain has approved Roche's (

Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways while studying novel, biology-driven . . . This content is for paid …

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg . . . This content is for paid subscribers. Please click here to subscribe or …

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM  TODAY CymaBay Therapeutics, Inc. (CBAY) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic diseases with high unmet need, announced that it will host a conference call and live audio webcast Today, Thursday . . . This content is for paid …